The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Robert Dreicer

Department of Solid Tumor Oncology

Taussig Cancer Institute

Cleveland Clinic

Cleveland

Ohio

[email]@ccf.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio. 2000 - 2012
  • Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. 2007
  • Department of Medicine, Cleveland Clinic Lerner College of Medicine, Cleveland, OH 44195, USA. 2006
  • Department of Hematology, Cleveland Clinic, USA. 2000
  • Department of Internal Medicine, The University of Iowa, and The University of Iowa Cancer Center, Iowa City, USA. 1999

References

  1. Systemic therapy for advanced adrenal cancer. Dreicer, R. J. Surg. Oncol (2012) [Pubmed]
  2. Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. Dreicer, R., Garcia, J., Hussain, M., Rini, B., Vogelzang, N., Srinivas, S., Somer, B., Zhao, Y.D., Kania, M., Raghavan, D. Invest. New. Drugs (2011) [Pubmed]
  3. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Dreicer, R., Li, H., Stein, M., DiPaola, R., Eleff, M., Roth, B.J., Wilding, G. Cancer (2009) [Pubmed]
  4. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Dreicer, R., Stadler, W.M., Ahmann, F.R., Whiteside, T., Bizouarne, N., Acres, B., Limacher, J.M., Squiban, P., Pantuck, A. Invest. New. Drugs (2009) [Pubmed]
  5. Current status of cytotoxic chemotherapy in patients with metastatic prostate cancer. Dreicer, R. Urol. Oncol. (2008) [Pubmed]
  6. Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group. Dreicer, R., Li, H., Cooney, M.M., Wilding, G., Roth, B.J. Cancer (2008) [Pubmed]
  7. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Dreicer, R., Li, S., Manola, J., Haas, N.B., Roth, B.J., Wilding, G. Cancer (2007) [Pubmed]
  8. Lenalidomide: immunomodulatory, antiangiogenic, and clinical activity in solid tumors. Dreicer, R. Curr. Oncol. Rep (2007) [Pubmed]
  9. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Dreicer, R., Petrylak, D., Agus, D., Webb, I., Roth, B. Clin. Cancer Res. (2007) [Pubmed]
  10. Chemotherapy for muscle-invasive bladder cancer in the perioperative setting: current standards. Dreicer, R. Urol. Oncol. (2007) [Pubmed]
  11. Chemotherapy for advanced prostate cancer: docetaxel and beyond. Dreicer, R. Hematol. Oncol. Clin. North Am. (2006) [Pubmed]
  12. Tyrosine kinase inhibitors compared with cytokine therapy for metastatic renal cell carcinoma: overview of recent clinical trials differentiating clinical response and adverse effects. Dreicer, R. Clinical. Genitourinary. Cancer (2006) [Pubmed]
  13. Overview of advanced urothelial cancer trials of the Eastern Cooperative Oncology Group. Dreicer, R., Roth, B., Wilding, G. Cancer (2003) [Pubmed]
  14. Phase II trial of GM-CSF in advanced prostate cancer. Dreicer, R., See, W.A., Klein, E.A. Invest. New. Drugs (2001) [Pubmed]
  15. Locally advanced and metastatic bladder cancer. Dreicer, R. Curr. Treat. Options. Oncol (2001) [Pubmed]
  16. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. Dreicer, R., Manola, J., Roth, B.J., Cohen, M.B., Hatfield, A.K., Wilding, G. J. Clin. Oncol. (2000) [Pubmed]
  17. The evolving role of hormone therapy in advanced prostate cancer. Dreicer, R. Cleve. Clin. J. Med (2000) [Pubmed]
  18. Phase II trial of suramin in patients with metastatic renal cell carcinoma. Dreicer, R., Smith, D.C., Williams, R.D., See, W.A. Invest. New. Drugs (1999) [Pubmed]
 
WikiGenes - Universities